NeuroMetrix to Present at Canaccord Genuity 6th Annual Cardiovascular, Aesthetics & Metabolic Disorders ConferenceWALTHAM, Mass.--(BUSINESS WIRE)--Nov. 29, 2011--
NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on
the diagnosis and treatment of the neurological complications of
diabetes, today announced that
Shai N. Gozani M.D., Ph.D., President and
Chief Executive Officer, is scheduled to speak at the Canaccord Genuity 6
th
Annual
Cardiovascular, Aesthetics & Metabolic Disorders Conference at
the
St. Regis Hotel,
San Francisco, CA on
December 6, 2011. Dr. Gozani
intends to provide an update on the Company’s business activities and on
its new product NC-stat® DPNCheck
TM for testing of systemic
neuropathies such as diabetic peripheral neuropathy (DPN).
NeuroMetrix's presentation is scheduled for Tuesday, December 6, 2011 at
2:40 pm (Pacific Daylight Time), 5:40 pm (Eastern Daylight Time). A live
audio webcast will be available on the investor relations section of the
corporate website - www.neurometrix.com.
This webcast will be archived after the live event.
About NeuroMetrix
NeuroMetrix is a medical device company focused on the diagnosis and
treatment of the neurological complications of diabetes. The Company
currently markets products for the detection, diagnosis, and monitoring
of diabetic neuropathies such as diabetic peripheral neuropathy and
median neuropathy (carpal tunnel syndrome). For more information, please
visit http://www.neurometrix.com.
Source: NeuroMetrix, Inc.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
Chief
Financial Officer
neurometrix.ir@neurometrix.com
